Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nova Mentis Life Sciences Corp (OP: NMLSF )

0.0062 UNCHANGED
Last Price Updated: 2:41 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nova Mentis Life Sciences Corp

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started < 
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a... 
Via Benzinga
Nova Mentis Is Looking To Treat Autism With Psilocybin
Nova Mentis Life Science Corp. (OTCQB: NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a ... 
Via Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a... 
Via Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc. 
Via Benzinga
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science... 
Via Benzinga
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops 
Via Benzinga
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry,... 
Via Benzinga
Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)... 
Via Newsfile
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
Canadian-based psychedelics company Nova Mentis Life Science Corp. 
Via Benzinga
Nova Mentis Completes Production of Psilocybin Microdose Capsules
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)... 
Via Newsfile
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB: NMLSF) is filing new provisional patent applications to the U.S. 
Via Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. 
Via Benzinga
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
Nova Mentis Life Science Corp. (OTCQB: NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently... 
Via Benzinga
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. ... 
Via Benzinga
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
Nova Mentis Life Science Corp (OTCQB: NMLSF) is a biotechnology company focused on psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. The... 
Via Benzinga
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis
The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application  to Health Canada   
Via Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Detroit Decriminalizes Psychedelics 
Via Benzinga
Exposures Product Safety
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
The Week In Psychedelics 
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.